Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Seddon B, Dehbi H, Nash S, Forsyth S, Tirabosco R, Küver K, Jamieson D, Veal G, Marples M, Ali N, Benson C, Wood Z, Rothermundt C, Cowie F, Woll P, Leahy M, Whelan J, Strauss S, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 2017
04.09.2017
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
04.09.2017
Lancet Oncol 2017
Seddon Beatrice, Dehbi Hakim-Moulay, Nash Stephen, Forsyth Sharon, Tirabosco Roberto, Küver Katja, Jamieson David, Veal Gareth J, Marples Maria, Ali Nasim, Benson Charlotte, Wood Zoe, Rothermundt Christian, Cowie Fiona, Woll Penella J, Leahy Michael, Whelan Jeremy, Strauss Sandra J, Beare Sandy
Weiter
